The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...

A retrospective cohort study suggested that users of GLP-1 receptor agonists had a 7% higher incidence of new-onset diabetic retinopathy. In patients with existing diabetic retinopathy, use of GLP-1 ...

About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic ...

The aim of this paper is to review anterograde degeneration throughout the anterior visual pathway, particularly in the optic tracts, the lateral geniculate nucleus, the optic radiations and the ...

The study found a median of 3.3 years between the initiation of GLP-1 RA use and the incidence of NAION. An increased risk for NAION was seen in association with 2 GLP-1 RAs: hazard ratios, 1.39 for ...

A Medicare cohort study of nearly 4 million older patients with type 2 diabetes found 2 in 1000 developed nonarteritic anterior ischemic optic neuropathy (NAION) over a period of more than 3 years.

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. Following a review of ...

Nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss, is a “very rare” side effect of treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, ...